Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
2(17%)
Results Posted
44%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
3
25%
Ph phase_3
4
33%
Ph phase_2
4
33%

Phase Distribution

3

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (27.3%)
Phase 24 (36.4%)
Phase 34 (36.4%)

Trials by Status

terminated18%
completed975%
recruiting217%

Recent Activity

2 active trials
Showing 5 of 12
recruitingphase_2

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

NCT04597437
completedphase_2

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

NCT04494412
recruitingphase_2

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

NCT05648448
completedphase_2

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

NCT04867707
completedphase_3

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04597437Phase 2

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Recruiting
NCT04494412Phase 2

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

Completed
NCT05648448Phase 2

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Recruiting
NCT04867707Phase 2

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

Completed
NCT01231620Phase 3

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

Completed
NCT01199744

Relenza® Sentinel Site Monitoring Program in Japan

Completed
NCT00989404Phase 1

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Completed
NCT02377401Phase 1

Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults

Completed
NCT00784784Phase 3

Zanamivir Versus Trivalent Split Virus Influenza Vaccine

Completed
NCT01459081Phase 3

Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

Completed
NCT00979667Phase 3

A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection

Terminated
NCT00921726Phase 1

Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12